1. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies. (September 2015) Authors: Ahn, M.J.; Tsai, C.M.; Yang, J.C.H.; Shepherd, F.A.; Satouchi, M.; Kim, D.W.; Bazhenova, L.; Hirashima, T.; Rukazenkov, Y.; Cantarini, M.; Mann, H.; Ramalingam, S.S.; Mitsudomi, T.; Jänne, P.A.; Goss, G.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies. (September 2015) Authors: Goss, G.D.; Yang, J.C.H.; Ahn, M.J.; Tsai, C.M.; Bazhenova, L.; Sequist, L.V.; Ramalingam, S.S.; Shepherd, F.A.; Ghiorghiu, S.; Cantarini, M.; Mann, H.; Mitsudomi, T.; Jänne, P.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases. (January 2015) Authors: Gettinger, S.N.; Bazhenova, L.; Salgia, R.; Langer, C.J.; Gold, K.A.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Narasimhan, N.I.; Dorer, D.J.; Rivera, V.M.; Clackson, T.; Haluska, F.G.; Camidge, D.R. Journal: Lung cancer Issue: Volume 87(2015)Supplement 1 Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases. Issue 1 (January 2015) Authors: Gettinger, S.N.; Bazhenova, L.; Salgia, R.; Langer, C.J.; Gold, K.A.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Narasimhan, N.I.; Dorer, D.J.; Rivera, V.M.; Clackson, T.; Haluska, F.G.; Camidge, D.R. Journal: Lung cancer Issue: Volume 87:Issue 1(2015:Jan.) Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. (December 2016) Authors: Drilon, A.; Marwan, F.; Fu, S.; Patel, M.R.; Olszanski, A.J.; Lockhart, A.C.; Liu, S.V.; Bazhenova, L.; Seery, T.; Nikolinakos, P.; Patel, R.; Oliver, J.W.; Multani, P.S.; Wang, D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET. (October 2020) Authors: Hong, D.; Bazhenova, L.; Cho, B.C.; Sen, S.; Ponz-Sarvise, M.; Heist, R.; Zimmerman, Z.; Le, X.; Xuan, D.; Junming, Z.; Lee, J. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation. (October 2020) Authors: Jänne, P.A.; Rybkin, I.I.; Spira, A.I.; Riely, G.J.; Papadopoulos, K.P.; Sabari, J.K.; Johnson, M.L.; Heist, R.S.; Bazhenova, L.; Barve, M.; Pacheco, J.M.; Leal, T.A.; Velastegui, K.; Cornelius, C.; Olson, P.; Christensen, J.G.; Kheoh, T.; Chao, R.C.; Ou, S.H.I. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in patients (pts) with advanced solid tumors. (December 2016) Authors: Subbiah, V.; Combest, A.; Grilley-Olson, J.; Sharma, N.; Andrews, E.; Bobe, I.; Balkissoon, J.; Camp, A.; Masada, A.; Reitsma, D.; Bazhenova, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022) Authors: Hong, D.; Shergill, A.; Bazhenova, L.; Cho, B.C.; Heist, R.; Moreno, V.; Falchook, G.S.; Nagasaka, M.; Cassier, P.; Besse, B.; Kim, D.W.; Yoon, S.; Le, X.; Zhao, T.; Atwal, S.; Park, E.; Lee, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). (October 2022) Authors: Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y.C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B.C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗